La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Spyre Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Spyre Therapeutics ha un patrimonio netto totale di $374.4M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $436.1M e $61.7M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$426.00m
Patrimonio netto	US$374.39m
Totale passività	US$61.68m
Totale attività	US$436.07m

Aggiornamenti recenti sulla salute finanziaria

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Recent updates

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08

Aeglea BioTherapeutics EPS misses by $0.14

May 10

Aeglea completes patient randomization in late-stage pegzilarginase trial

May 03

What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition

Mar 17

We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully

Feb 10

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $435.7M ) di SYRE superano le sue passività a breve termine ( $22.1M ).

Passività a lungo termine: Le attività a breve termine di SYRE ( $435.7M ) superano le sue passività a lungo termine ( $39.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SYRE è esente da debiti.

Riduzione del debito: SYRE non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SYRE ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: SYRE ha una liquidità sufficiente per 2.8 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 14.1 % ogni anno.

Spyre Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Recent updates

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) acquired Spyre Therapeutics, Inc. for $1.42 million.

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Aeglea BioTherapeutics Announces Resignation of Sandesh Mahatme as Director

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2000 Dynamic Index

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Biotherapeutics, Inc. Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Consensus revenue estimates increase by 36%

Price target decreased to US$9.86

Price target decreased to US$11.00

Aeglea BioTherapeutics, Inc. Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Consensus revenue estimates increase by 76%

President recently bought US$281k worth of stock

Consensus forecasts updated

Price target decreased to US$11.00

Aeglea Biotherapeutics, Inc. Announces Resignation of Sara Brownstein as Class I Director of the Board

Independent Director recently bought US$550k worth of stock

Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

Price target decreased to US$12.43

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Chief Financial Officer recently bought US$263k worth of stock

Consensus revenue estimates increase to US$17.9m

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aeglea BioTherapeutics, Inc. Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for Treatment of Arginase 1 Deficiency in Journal of Inherited Metabolic Disease

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2500 Growth Index

Aeglea Biotherapeutics Doses First Patient in A Phase 1/2 Clinical Trial of Agle-177, A Potential First-In-Class Treatment for Homocystinuria

Aeglea BioTherapeutics EPS misses by $0.14

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency